Navigation Links
CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Date:2/26/2008

PALO ALTO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the fourth quarter and full year ended December 31, 2007.

For the quarter ended December 31, 2007, the Company reported a net loss of $34.1 million, or $0.57 per share. This compares to a net loss of $68.1 million, or $1.18 per share, for the same quarter in 2006 and $34.2 million, or $0.58 per share, for the prior quarter ended September 30, 2007. For the year ended December 31, 2007, the Company reported a net loss of $181.0 million, or $3.05 per share, compared to a net loss of $274.3 million, or $5.49 per share, for the year ended December 31, 2006.

For the quarter ended December 31, 2007, the Company recorded total revenues of $22.4 million which consisted of $20.9 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) and $1.5 million of collaborative research revenue. The $20.9 million of net product sales of Ranexa in the quarter ended December 31, 2007 represents an increase of 14 percent compared to the $18.4 million of net product sales recorded in the prior quarter ended September 30, 2007 and an increase of 132 percent compared to the $9.0 million of net product sales in the same quarter of the prior year. The fourth quarter 2007 collaborative research revenue includes revenue primarily related to the reimbursement of certain regadenoson development costs from our collaborative partner.

For the full year ended December 31, 2007, the Company recorded revenue of $82.8 million, consisting of $66.7 million of net product sales of Ranexa and $16.2 million of collaborative research revenue which includes a $7.0 million milestone payment for submission of a new d
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
2. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
3. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
4. CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
5. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
6. Ocera Therapeutics Closes $35.5 Million Series C Financing
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
8. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
9. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
10. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
11. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  MiMedx Group, Inc. (NASDAQ: ... of patent protected regenerative biomaterials and bioimplants processed ... another peer-reviewed clinical study.    The ... Controlled Clinical Trial Evaluating the Use of ... Multi-layer Compression Therapy vs. Multi-layer Compression Therapy Alone ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction of a ... This addition to the company’s industry-leading line of custom ... available in 125 or 250 gallon capacities. It ... or less. , The new pre-engineered TerraPure tank offers ... TerraPure tank line – plus quick turnaround. An ...
(Date:9/17/2014)... , Sept. 17, 2014 Veracyte, Inc. ... company pioneering the field of molecular cytology, today announced ... officer. Mr. Hall joined Veracyte in 2010 ... entry into endocrinology. Since 2012, he has led sales, ... managed care and billing functions. As chief operating officer, ...
(Date:9/17/2014)... , September 17, 2014 ... mode of action from a truly novel ... MGB Biopharma, a biopharmaceutical company ... announces today that it has secured £4.0m ... lead antibacterial, MGB-BP-3, against a range of ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Stock Exchange Symbol: MSEDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), announced that effective on ... purchase warrants, each of which entitles the holder to ... of $5.00 per share, will be extended from March ...
... B.C. Technology Promises to Revolutionize Food Processing, ... Corporation (TSX-V: ENW) ("EnWave" or "the Company") today ... of its continuous nutraREV(TM) food dehydration equipment to ... of B.C.,s largest blueberry producers. With this sale, ...
... of "In the Zone for UC" Campaign, Centocor Ortho ... Colitis Foundation of America for Each Point Pisani Scores ... Ortho Biotech Inc. announced today a partnership with professional ... colitis (UC) and funding to support continued education and ...
Cached Biology Technology:BioMS Medical warrant extension 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... spelled doom for the dinosaurs 66 million years ago ... much greater extent than their deciduous peers, according to ... published in the journal PLOS Biology . ... thousands of fossilized leaves of angiosperms flowering ... reconstruct the ecology of a diverse plant community thriving ...
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3
... has found all forms of tobacco exposure, whether that be ... of heart attack. , The study by professors Salim Yusuf ... Medicine at McMaster University and Hamilton Health Sciences in Hamilton, ... In collaboration with colleagues from 52 countries, they calculated the ...
... Researchers have found that abnormal stimulation of a ... cells in adults causes invasive tumor-like growths in ... to regress--a finding the researchers said suggests a ... called malignant gliomas. , Arturo Alvarez-Buylla and Erica ...
... savannas contain 70% of the world's plants and are critical ... project involving researchers from the Leeds Earth and Biosphere Institute ... sensitive areas. , The researchers think we may be at ... the rainforests to shrink, so increasing the amount of carbon ...
Cached Biology News:Global study shows all tobacco bad for the heart 2Global study shows all tobacco bad for the heart 3Possible birthplace of malignant brain tumors identified 2The vicious cycle of rainforest destruction 2
... C1 Plus is a modular confocal system ... with an ultra-compact and lightweight design. The ... Plusboost optical performance to 400nm andits bi-directional ... support for X and Y scan axes ...
... integrated digital microscope and camera system that ... optical adjustment or software installation. Built on ... combines simplicity and advanced technology for users ... viewing of a macro image and a ...
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... The Fujifilm Life Science LAS-3000 ... technology with a simplified user interface, ... a wide range of modularities. The ... applications, and the perfect standard system ...
Biology Products: